Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Sep 08, 2022 1:03pm
97 Views
Post# 34949806

RE:RE:RE:RE:RE:RE:Bicycle Therap. - encouraging in ovarian

RE:RE:RE:RE:RE:RE:Bicycle Therap. - encouraging in ovarianSpousal patience has been severely tested for many! We owe them bigly should the bet come in.

I assume the required retirement withdrawal (RMD) is year end --just so THTX knows.  According to CEO, we should hope to have one, some or many data points by year end. Let's hope enrollment in ALL the centers has been strong and this is right.

I would love to know how it is going in each center. We have sort of sussed out that it's reasonably high on the usage list at both Pennsylvania and Karamos. But Crowley seems primarily interested in prostate, which seems odd. We've never heard much back from MD Anderson, START Midwest or Cedars Sinai. The big population centers where one should expect to see the highest enrollment would be Dallas (Crowley), Houston (Anderson), Detroit (Karamos) and LA (Sinai). We have scant data from most of those.

Lee430 wrote: I ran out of patience some time ago, however, my wife has been graciously lending me some of her seemingly unlimited supply of patience, especially when it comes to me.

Note to Thera, Pleeezzz get us above the penny stock range before my 2022 RMD is due as I sure would hate to be forced to sell at this SP.

Bucknelly21 wrote: I am so tired of waiting....




<< Previous
Bullboard Posts
Next >>